According to our (Global Info Research) latest study, the global Benzoic Acid Retagliptin Tablets market size was valued at US$ 61.43 million in 2025 and is forecast to a readjusted size of US$ 32.50 million by 2032 with a CAGR of 6.1% during review period.
Fultagliptin Benzoate Tablets are innovative domestic oral hypoglycemic drugs belonging to dipeptidyl peptidase 4 (DPP-4) inhibitors. It selectively inhibits the activity of dipeptidyl peptidase 4, prolongs the action time of incretins in the body, stably regulates the secretion of insulin and glucagon, and thereby effectively controls blood glucose. With mild hypoglycemic effect and good tolerance, it is mainly applied to improve blood glucose and carry out chronic disease management in adult patients with type 2 diabetes, and occupies an important position in clinical hypoglycemic treatment.In 2025, global Fultagliptin Benzoate Tablets production reached approximately 2.1 million bottles.
As a domestic Class 1 innovative DPP-4 inhibitor, Fultagliptin Benzoate Tablets boast differentiated clinical advantages and policy support, enjoying broad development prospects in the type 2 diabetes treatment market. Independently developed by Salubris Pharmaceuticals, the drug was approved for marketing in 2024 and quickly included in the National Medical Insurance Catalogue, which greatly improves patients’ medication accessibility and market access capability. In clinical practice, it features a low risk of hypoglycemia, neutral impact on body weight and favorable tolerance. It can be used as monotherapy or combined with drugs such as Metformin to meet the treatment needs of patients at different disease stages. At present, the domestic DPP-4 inhibitor market is still dominated by imported original research drugs, while the supply of domestic innovative varieties is relatively insufficient. As one of the few domestic original research products, Fultagliptin Benzoate Tablets is expected to gradually replace imported products by virtue of price advantages and channel expansion. Meanwhile, with the rising prevalence of diabetes, the continuous improvement of the chronic disease management system and the growing demand in primary medical markets, this product has long-term sales growth potential. Driven by medical insurance policies, clinical guideline recommendations and corporate academic promotion, Fultagliptin Benzoate Tablets will hopefully become a key growth driver in the domestic hypoglycemic drug market and promote the breakthrough and development of domestic innovative drugs in the field of metabolic diseases.
This report is a detailed and comprehensive analysis for global Benzoic Acid Retagliptin Tablets market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Benzoic Acid Retagliptin Tablets market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Benzoic Acid Retagliptin Tablets market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Benzoic Acid Retagliptin Tablets market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Benzoic Acid Retagliptin Tablets market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Benzoic Acid Retagliptin Tablets
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Benzoic Acid Retagliptin Tablets market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Salubris Pharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Benzoic Acid Retagliptin Tablets market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
6 mg
12 mg
Market segment by Combination Therapy
Combined With Metformin
Combined With Sulfonylureas
Market segment by Sales Channel
Hospital
Retail
Online
Market segment by Application
Type 2 Diabetes Mellitus
Auxiliary Blood Glucose Regulation
Chronic Metabolic Disease Management
Others
Major players covered
Salubris Pharmaceuticals
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Benzoic Acid Retagliptin Tablets product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Benzoic Acid Retagliptin Tablets, with price, sales quantity, revenue, and global market share of Benzoic Acid Retagliptin Tablets from 2021 to 2026.
Chapter 3, the Benzoic Acid Retagliptin Tablets competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Benzoic Acid Retagliptin Tablets breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Benzoic Acid Retagliptin Tablets market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Benzoic Acid Retagliptin Tablets.
Chapter 14 and 15, to describe Benzoic Acid Retagliptin Tablets sales channel, distributors, customers, research findings and conclusion.
Summary:
Get latest Market Research Reports on Benzoic Acid Retagliptin Tablets. Industry analysis & Market Report on Benzoic Acid Retagliptin Tablets is a syndicated market report, published as Global Benzoic Acid Retagliptin Tablets Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Benzoic Acid Retagliptin Tablets market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.